Previous Close | 0.0084 |
Open | 0.0078 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0076 - 0.0085 |
52 Week Range | 0.0030 - 0.0122 |
Volume | |
Avg. Volume | 1,131,790 |
Market Cap | 1.824M |
Beta (5Y Monthly) | -3.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited ...
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd ...
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and ...